Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : The New QUALCOMM - Coming Into Buy Range -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (954)	8/16/2007 9:31:12 PM
From: Ruffian	Respond to of 9129

<OT> GET READY BABY Q! Adventrx cancer injection gets FDA fast track Thu Aug 16, 2007 6:19AM EDT Aug 16 (Reuters) - Adventrx Pharmaceuticals Inc. (ANX.A: Quote, Profile, Research) said U.S. health regulators granted fast-track designation for its treatment for metastatic colorectal cancer. Adventrx's CoFactor injection is currently being investigated in a pivotal late stage study, whose main goal is to achieve progression-free survival, the company said in a statement. Fast-track designation speeds the development and review of treatments intended for serious or life-threatening conditions that show potential to meet an unmet medical need. (Reporting by Esha Dey in Bangalore) © Reuters 2007. All rights reserved.